Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clene Inc
(NQ:
CLNN
)
4.800
+0.010 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clene Inc
< Previous
1
2
3
4
Next >
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases
December 14, 2023
Via
Investor Brand Network
Stem Cell Therapy Shows Promise in Halting Progression of Cognitive Decline in MS Patients
December 11, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
December 08, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’
September 28, 2023
Via
Investor Brand Network
The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
December 08, 2023
Via
Investor Brand Network
Study Suggests Parkinson’s Could Be Linked to Onset of Stroke, Heart Disease
November 29, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
November 22, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
November 16, 2023
Via
Investor Brand Network
Blood Test Could Detect Worsening MS Symptoms in Patients
November 15, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
November 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
November 07, 2023
Via
Investor Brand Network
Exposures
Product Safety
Australian Study Finds Way to Detect Parkinson’s Prior to Symptom Onset
November 03, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
October 30, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
October 25, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology
October 17, 2023
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS
October 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast
October 10, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS
October 05, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal
September 28, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Significant Long-Term Survival Improvement Data from ALS Trial
September 25, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $40M Public Offering
June 22, 2023
Via
Investor Brand Network
Clene: Still in the Running for ALS
February 14, 2023
New York, New York, United States - 02-14-2023 (PR Distribution™) -
Via
PR Distribution
Topics
Death
Exposures
Death
Product Safety
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
February 13, 2023
From
Clene Inc.
Via
GlobeNewswire
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
January 11, 2023
From
Clene Inc.
Via
GlobeNewswire
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
December 27, 2022
From
Clene Inc.
Via
GlobeNewswire
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
December 12, 2022
Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor Hogan
From
Clene Inc.
Via
GlobeNewswire
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
November 28, 2022
From
Clene Inc.
Via
GlobeNewswire
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
November 07, 2022
From
Clene Inc.
Via
GlobeNewswire
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
October 31, 2022
From
Clene Inc.
Via
GlobeNewswire
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
October 03, 2022
From
Clene Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.